Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ASP Isotopes Inc. (NASDAQ: ASPI) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on ASP Isotopes’ activities as a development stage advanced materials company focused on isotope enrichment technologies, as well as the work of its subsidiaries in nuclear fuels, helium, and related areas.
Through current reports on Form 8-K, ASP Isotopes discloses material events such as the closing of its acquisition of Renergen Limited, a helium and liquefied natural gas producer with operations at the Virginia Gas Project in South Africa. Other 8-K filings describe regulatory approvals for that transaction, private placements of convertible notes issued by its subsidiary Quantum Leap Energy LLC to fund laser enrichment production facilities, and confidential submission of a draft registration statement for a proposed initial public offering of Quantum Leap Energy’s Class A common stock.
The company’s 8-K filings also cover regulatory engagement in the United Kingdom by Quantum Leap Energy Ltd regarding potential High-Assay Low Enriched Uranium (HALEU) production, as well as the acquisition of assets from One 30 Seven Inc. to develop Creber Units for processing water-soluble nuclear waste. These documents provide formal descriptions of transaction terms, use of proceeds, conversion mechanics for notes, and related risk and disclosure language.
ASP Isotopes’ definitive proxy statement on Schedule 14A outlines governance matters, including the annual meeting agenda, director elections, auditor ratification, and voting procedures. The proxy materials also describe the company’s status as an emerging growth company and provide information on its capital structure and shareholder voting rights.
On Stock Titan, investors can use AI-powered tools to read summaries of these filings, quickly identify key sections, and navigate to specific topics such as capital raises, acquisitions, nuclear fuel cycle initiatives, or governance changes. Real-time updates from EDGAR ensure that new 8-Ks, proxy statements, and other relevant filings for ASPI are available as they are published, helping users follow how ASP Isotopes documents its strategic transactions, financing activities, and regulatory developments.
ASP Isotopes reports a major milestone at its Virginia Gas Project, completing all wells required for Phase 1 of the Renergen Helium Project about four months ahead of schedule. Drilling results from the Phase 1C campaign indicate reservoir gas flow rates that meet or exceed earlier type-curve estimates, easing historic constraints on plant utilisation and helium production.
The Phase 1 drilling program has now achieved the required cumulative nameplate flow rate, meaning remaining work to reach full output is largely engineering-focused. Some new wells are delivering gas flow rates up to 16 times those of certain earlier wells, and the company plans to tie these into the processing plant over the coming months. After planned completion of Phase 1 during 2026, ASP Isotopes expects production of 2,500 GJ per day of LNG and 58 MCF per day of liquid helium, rising after Phase 2 to 34,000 GJ per day of LNG and 895 MCF per day of liquid helium.
The update comes as global helium supply tightens due to the closure of the Strait of Hormuz and reported damage at Ras Laffan in Qatar, which supplied about 2.3 billion scf of helium in 2025. The company highlights South Africa’s geopolitical neutrality and backing from the U.S. International Development Finance Corporation as advantages for positioning the Virginia Gas Project as a significant new source of liquid helium.
ASP Isotopes Inc. announced that CEO Paul Mann will participate in a fireside chat at Canaccord Genuity’s 2nd Annual CG Virtual Sustainability Summit on March 12, 2026, at 3:20 p.m. ET. The event will be held virtually and focuses on sustainability-related topics.
A live audio webcast of the presentation will be available in the Investors section of the company’s website, with a replay accessible within 48 hours. The company highlights its work on proprietary isotope enrichment technologies for applications in nuclear medicine, advanced semiconductors, and nuclear energy, and includes extensive cautionary language about forward-looking statements and related risks.
ASP Isotopes Inc. COO Robert Ainscow reported an open-market sale of 8,438 shares of common stock. The transaction occurred on March 6, 2026 at a weighted average price of $5.439 per share.
The sale was a "sell to cover" under a Rule 10b5-1 trading plan adopted on June 9, 2025 to cover tax withholding obligations from vesting restricted stock awards. After this transaction, Ainscow directly owns 1,537,817 ASP Isotopes common shares.
Ainscow Robert filed a Form 144 reporting a proposed sale of 300,000 shares of common stock of Independent Trading Group (ITG) Inc., described as acquired as compensation (Restricted Stock Award) on 09/06/2024. The filing also lists securities sold during the past three months: 8,438 shares on 12/08/2025 with an amount shown of 52,340.91.
ASP Isotopes, through its subsidiary Quantum Leap Energy (QLE), has signed a non-binding memorandum of understanding with a large publicly traded U.S. energy company that operates nuclear power stations. The partner will evaluate options to support QLE’s plans to build advanced nuclear fuel cycle facilities in the United States.
The planned facilities would produce high assay low enriched uranium (HALEU) and low enriched uranium plus (LEU+), and provide uranium conversion and deconversion services. QLE aims to supply HALEU for advanced and small modular reactors and offer LEU+ to the existing reactor fleet to lengthen refueling intervals, cut costs, and increase power output.
QLE positions this initiative as a step toward strengthening the domestic nuclear fuel supply chain amid a federal ban on Russian uranium imports starting in 2028 and growing demand from next-generation reactor developers.
ASP Isotopes’ subsidiary Quantum Leap Energy appointed Nate Salpeter, Ph.D., as Chief Technology Officer. He is a recognized expert in fluid dynamics and energy technology optimization with more than 15 years of experience building computational, experimental, and engineering programs in advanced nuclear and thermal systems.
Dr. Salpeter previously held senior technical roles at TerraPower and Kairos Power, where he helped establish core fluid dynamics and modeling capabilities for next‑generation reactor projects. At Quantum Leap Energy, he will focus on optimizing in‑licensed and proprietary technologies, implementing rapid learning cycles, and leading methodical de‑risking to support commercialization of the company’s nuclear fuel and clean energy technologies.
The announcement highlights Quantum Leap Energy’s strategy as a development‑stage nuclear fuels company using Aerodynamic Separation Process and Quantum Enrichment technologies to address gaps in the nuclear fuel cycle for advanced reactors, small modular reactors, and fusion systems, supported by partnerships with leading industry and research organizations.
ASP Isotopes Inc. Executive Chairman Paul Elliot Mann reported an open-market sale of 162,153 shares of common stock at a weighted average price of $5.436 per share. According to the disclosure, these were “sell to cover” transactions under a Rule 10b5-1 trading plan to satisfy tax withholding on the quarterly vesting of a restricted stock award.
After these sales, Mann held 7,597,385 shares of ASP Isotopes common stock directly. The filing notes the shares were sold in multiple transactions at prices ranging from $5.10 to $5.57 per share.
Independent Trading Group Inc. (ASPI) filed a Form 144 reporting a proposed sale of 1,441,361 shares of common stock, listed as acquired as compensation under a restricted stock award on 04/14/2025.
The filing identifies the securities as common stock to be sold through NASDAQ and cites the 04/14/2025 grant date; cash‑flow treatment and exact planned sale timing are not shown in the excerpt.
ASP Isotopes’ subsidiary Quantum Leap Energy has deepened its collaboration with the South African Nuclear Energy Corporation (Necsa) by signing a Pre-Implementation Services Contract for a planned High Assay Low Enriched Uranium (HALEU) enrichment facility at Necsa’s Pelindaba site.
Under the agreement, Necsa will provide facilities, infrastructure, utilities and services to support the siting, design, construction, commissioning and operation of the enrichment facility. A joint committee with representatives from both parties will oversee implementation, aiming to bring QLE’s HALEU production capabilities to market readiness.
The partnership combines QLE’s proprietary Aerodynamic Separation Process and Quantum Enrichment technologies with Necsa’s established nuclear infrastructure and global networks. It targets growing demand for HALEU, a key fuel for small modular and other advanced reactors, as advanced nuclear projects scale to serve data centers and industrial electrification.
ASP Isotopes Inc., through its wholly owned subsidiary Quantum Leap Energy (QLE), has created a Strategic Advisory Board to support its plans in the nuclear fuel sector and appointed two initial members, nuclear engineering academic leader Mary Lou Dunzik-Gougar and advanced materials executive Kevin Kramer.
The board is expected to guide QLE as it develops proprietary technologies to address inefficiencies, environmental concerns, and supply chain vulnerabilities across the nuclear fuel cycle, including front-end enrichment activities and back-end waste treatment technologies for advanced reactors, fusion systems, and the existing nuclear fleet.